EA031321B1 - Нуклеиновые кислоты, кодирующие белки вируса гриппа, композиции на их основе и способы профилактики и лечения - Google Patents

Нуклеиновые кислоты, кодирующие белки вируса гриппа, композиции на их основе и способы профилактики и лечения Download PDF

Info

Publication number
EA031321B1
EA031321B1 EA201201025A EA201201025A EA031321B1 EA 031321 B1 EA031321 B1 EA 031321B1 EA 201201025 A EA201201025 A EA 201201025A EA 201201025 A EA201201025 A EA 201201025A EA 031321 B1 EA031321 B1 EA 031321B1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza
virus
hemagglutinin
nucleic acid
seq
Prior art date
Application number
EA201201025A
Other languages
English (en)
Russian (ru)
Other versions
EA201201025A1 (ru
Inventor
Дэвид Б. Уэйнер
Цзянь Янь
Мэттью П. Морроу
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44309124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA031321(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA201201025A1 publication Critical patent/EA201201025A1/ru
Publication of EA031321B1 publication Critical patent/EA031321B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EA201201025A 2010-01-26 2011-01-26 Нуклеиновые кислоты, кодирующие белки вируса гриппа, композиции на их основе и способы профилактики и лечения EA031321B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/694,238 US8298820B2 (en) 2010-01-26 2010-01-26 Influenza nucleic acid molecules and vaccines made therefrom
PCT/US2011/022642 WO2011094358A1 (en) 2010-01-26 2011-01-26 Influenza nucleic acid molecules and vaccines made therefrom

Publications (2)

Publication Number Publication Date
EA201201025A1 EA201201025A1 (ru) 2013-01-30
EA031321B1 true EA031321B1 (ru) 2018-12-28

Family

ID=44309124

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201201025A EA031321B1 (ru) 2010-01-26 2011-01-26 Нуклеиновые кислоты, кодирующие белки вируса гриппа, композиции на их основе и способы профилактики и лечения
EA201891712A EA201891712A3 (ru) 2010-01-26 2011-01-26 Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891712A EA201891712A3 (ru) 2010-01-26 2011-01-26 Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них

Country Status (15)

Country Link
US (4) US8298820B2 (enExample)
EP (2) EP3173103A1 (enExample)
JP (2) JP5992337B2 (enExample)
KR (2) KR20180118244A (enExample)
CN (2) CN102753200B (enExample)
AU (1) AU2011209626B2 (enExample)
BR (1) BR112012018587A2 (enExample)
CA (1) CA2786901A1 (enExample)
EA (2) EA031321B1 (enExample)
ES (1) ES2600890T3 (enExample)
HK (1) HK1249139A1 (enExample)
IN (1) IN2012DN06289A (enExample)
MX (3) MX2012008651A (enExample)
WO (1) WO2011094358A1 (enExample)
ZA (1) ZA201307844B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP2013520172A (ja) * 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
AU2011302360B2 (en) 2010-09-14 2015-01-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
AU2012214141B2 (en) 2011-02-11 2016-01-28 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis B virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
US20140236070A1 (en) * 2011-07-29 2014-08-21 Kate Broderick Linear expression cassettes and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
RU2653756C2 (ru) * 2012-02-07 2018-05-14 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
JP6175452B2 (ja) 2012-02-13 2017-08-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ヒトおよびトリｈ５ｎ１インフルエンザのための、計算で最適化した反応性の広い抗原
BR112014023900A2 (pt) 2012-03-30 2020-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polipeptídeo de hemaglutimina de influenza recombinante, molécula de ácido nucleicoisolada, vetor, célula isolada, partícula semelhante ao vírus da influenza, proteína de fusão, composição, e uso
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
AU2013352179B2 (en) 2012-11-27 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
WO2014093886A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Wt1 vaccine
MX2015007575A (es) * 2012-12-13 2016-03-15 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP6525949B2 (ja) * 2013-03-15 2019-06-05 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ボツリヌス菌の各血清型の重鎖を使用する１価または多価のボツリヌス神経毒素ワクチン
KR20150127586A (ko) 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 핵산 분자 및 이로부터 제조된 백신
DK2969005T3 (da) 2013-03-15 2020-01-20 The Resaerch Foundation For The State Univ Of New York Attenuerede influenzavira og -vacciner
US10398769B2 (en) * 2013-08-06 2019-09-03 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CA2926025A1 (en) * 2013-10-07 2015-04-16 The Trustees Of The University Of Pennsylvania Vaccines with interleukin-33 as an adjuvant
AU2015323944B2 (en) * 2014-10-01 2018-11-29 Inovio Pharmaceuticals, Inc. Vaccines having an antigen and interleukin-21 as an adjuvant
CN114010802A (zh) 2014-12-01 2022-02-08 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016153995A1 (en) * 2015-03-20 2016-09-29 The Trustees Of The University Of Pennsylvania Vaccines with cd40 ligand as an adjuvant
AU2017207448A1 (en) * 2016-01-15 2018-07-26 Etubics Corporation Methods and compositions for influenza vaccination
WO2017192947A1 (en) 2016-05-05 2017-11-09 Weiner, David Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
CN105999257A (zh) * 2016-05-11 2016-10-12 长春海基亚生物技术股份有限公司 无针注射流感疫苗系统与应用
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
AU2018392799A1 (en) 2017-12-22 2020-05-28 Codagenix, Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12064478B2 (en) * 2018-09-21 2024-08-20 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
CN111514287A (zh) * 2020-04-29 2020-08-11 河南大学 甲型流感通用型dna疫苗及其制备方法和应用
KR102818854B1 (ko) * 2021-07-29 2025-06-13 주식회사 에스엠엘바이오팜 발현 시스템 및 이를 이용한 핵산 기반 백신
CN114854777B (zh) * 2022-04-15 2024-06-25 中山大学 一种基于优化na序列的广谱流感疫苗及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299151A1 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
US20090169505A1 (en) * 2007-11-12 2009-07-02 Ruxandra Draghia-Akli Novel vaccines against multiple subtypes of influenza virus

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
AU625584B2 (en) 1989-03-08 1992-07-16 Health Research Inc. Recombinant poxvirus host selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
JP3004049B2 (ja) 1989-03-31 2000-01-31 ワシントン ユニバーシティー 病原性のないｐｈｏＰ型微生物を含有するワクチン
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
AU733628B2 (en) 1997-04-03 2001-05-17 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
WO2002028165A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
TWI290174B (en) 2002-11-04 2007-11-21 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
DK1628749T3 (da) 2003-05-30 2019-09-16 Vgxi Inc Anordninger og fremgangsmåder til biomateriel produktion
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
AU2005248375B2 (en) 2004-05-25 2010-12-16 Medimmune, Llc Influenza hemagglutinin and neuraminidase varians
KR20070100292A (ko) 2005-01-18 2007-10-10 보그워너 인코포레이티드 신속히 기동하는 캠샤프트 페이서의 작동을 통한 밸브이벤트 단축
EP1851238A4 (en) * 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
KR20090034297A (ko) * 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신
US20070286873A1 (en) 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
KR101999376B1 (ko) 2006-07-28 2019-07-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
KR101421760B1 (ko) 2006-10-17 2014-07-22 브이지엑스 파머시우티컬즈, 인크. 포유류의 세포의 전기천공용 전기천공 장치 및 이의 사용 방법
EP2111233A2 (en) 2006-12-29 2009-10-28 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
WO2008124331A1 (en) 2007-04-03 2008-10-16 Cytogenix, Inc. Novel sequences and dna vaccines against avian flu
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
ES2614802T3 (es) * 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
CN102781952B (zh) 2010-02-08 2015-09-02 宾夕法尼亚大学托管会 编码rantes的核酸分子、包含其的组合物以及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299151A1 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
US20090169505A1 (en) * 2007-11-12 2009-07-02 Ruxandra Draghia-Akli Novel vaccines against multiple subtypes of influenza virus

Also Published As

Publication number Publication date
US9884106B2 (en) 2018-02-06
MX2012008651A (es) 2012-08-23
US20130052222A1 (en) 2013-02-28
KR101912330B1 (ko) 2018-10-26
HK1249139A1 (zh) 2018-10-26
EA201201025A1 (ru) 2013-01-30
ZA201307844B (en) 2015-12-23
CN102753200B (zh) 2017-11-21
US20110182938A1 (en) 2011-07-28
EA201891712A3 (ru) 2019-05-31
MX357191B (es) 2018-06-29
ES2600890T3 (es) 2017-02-13
KR20180118244A (ko) 2018-10-30
US10363302B2 (en) 2019-07-30
EP2528626A1 (en) 2012-12-05
CN102753200A (zh) 2012-10-24
WO2011094358A1 (en) 2011-08-04
JP5992337B2 (ja) 2016-09-14
CA2786901A1 (en) 2011-08-04
AU2011209626A1 (en) 2012-08-09
CN107739736A (zh) 2018-02-27
EP2528626A4 (en) 2013-07-17
US9192660B2 (en) 2015-11-24
JP2016105728A (ja) 2016-06-16
MX2018008135A (es) 2021-11-16
US20180133307A1 (en) 2018-05-17
AU2011209626B2 (en) 2013-05-23
EA201891712A2 (ru) 2019-01-31
EP3173103A1 (en) 2017-05-31
WO2011094358A9 (en) 2012-01-05
US8298820B2 (en) 2012-10-30
EP2528626B1 (en) 2016-09-28
US20120064116A9 (en) 2012-03-15
KR20130048192A (ko) 2013-05-09
IN2012DN06289A (enExample) 2015-09-25
BR112012018587A2 (pt) 2020-09-01
JP2013517800A (ja) 2013-05-20
US20160030548A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
KR101912330B1 (ko) 인플루엔자 핵산 분자 및 이로부터 생산된 백신
KR101255419B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
KR20150127586A (ko) 인플루엔자 핵산 분자 및 이로부터 제조된 백신
JP7601916B2 (ja) 蝸牛および前庭細胞に核酸を送達するための物質および方法
KR102131276B1 (ko) 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
CN112979829B (zh) 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用
KR20180097631A (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
US11925685B2 (en) DNA antibody constructs encoding anti-ZIKV envelope antibodies
KR20200014780A (ko) 최적화된 핵산 항체 작제물
JP2019521702A (ja) インフルエンザウイルスを標的とするｄｎａモノクローナル抗体
CN114573716A (zh) 一种含ccl1的融合蛋白、制备方法及应用
US20220307054A1 (en) Modulation of t cell responses by ul18 of human cytomegalovirus
KR20220082033A (ko) 레트로바이러스의 계내 생성을 위한 생산자 바이러스
JP2021527080A (ja) インビボ翻訳後修飾のための組成物および方法
HK1149176B (en) Vaccines against multiple subtypes of influenza virus
CN114854777A (zh) 一种基于优化na序列的广谱流感疫苗及其应用
HK40014682B (zh) 新的对抗寨卡病毒的疫苗和用於对抗寨卡病毒的dna抗体构建体的组合
HK1189598B (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
HK1177150B (en) Influenza nucleic acid molecules and vaccines made therefrom
HK1189598A (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
HK1234438A1 (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
HK1234438A (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU